RECOMBINATE 500 IU

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Dostępny od:

TEVA MEDICAL MARKETING LTD.

Kod ATC:

B02BD05

Forma farmaceutyczna:

POWDER FOR SOLUTION FOR INJECTION

Droga podania:

I.V

Wyprodukowano przez:

BAXTER S.A., BELGIUM

Grupa terapeutyczna:

COAGULATION FACTOR VII

Wskazania:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Data autoryzacji:

2010-07-01